CARAT
Chimeric Antigen Receptors (CARs) for Advanced Therapies
- Description
CARAT will develop an innovative manufacturing platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR T cells including novel tracking tools. CARs (Chimeric Antigen Receptors) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T cells specifically towards killing of cancer cells. CARAT will establish complementary enabling technologies to obtain more effective and safer cellular products, improved gene delivery, better CARs design and innovative monitoring. Thereby, CARAT will deliver proof-of-principle for an innovative integrated solution to generate genetically modified ATMPs (advanced therapeutic medicinal products) that are specifically tailored towards cancer killing and thus serve patients with so far incurable solid tumours and hematologic malignancies.
- Coordinator
Related News
- Programme
- Horizon 2020 & sub-programmes
- Duration
- 48 months (January 2016 - December 2019)
- Project funding
- € 5,989,158.75
- Project partners
- 8
- Technology readiness level
- 4-7